- Home
- OABI vs RDIB Comparison
OABI vs RDIB Comparison
Compare OABI & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- RDIB
- Stock Information
- Founded
- OABI 2012
- RDIB 1937
- Country
- OABI United States
- RDIB United States
- Employees
- OABI N/A
- RDIB N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- OABI Health Care
- RDIB Consumer Discretionary
- Exchange
- OABI Nasdaq
- RDIB Nasdaq
- Market Cap
- OABI 239.0M
- RDIB 259.2M
- IPO Year
- OABI N/A
- RDIB N/A
- Fundamental
- Price
- OABI $1.58
- RDIB $11.50
- Analyst Decision
- OABI Strong Buy
- RDIB
- Analyst Count
- OABI 3
- RDIB 0
- Target Price
- OABI $6.67
- RDIB N/A
- AVG Volume (30 Days)
- OABI 544.6K
- RDIB 3.8K
- Earning Date
- OABI 11-04-2025
- RDIB 11-12-2025
- Dividend Yield
- OABI N/A
- RDIB N/A
- EPS Growth
- OABI N/A
- RDIB N/A
- EPS
- OABI N/A
- RDIB N/A
- Revenue
- OABI $21,094,000.00
- RDIB $219,213,000.00
- Revenue This Year
- OABI N/A
- RDIB $6.85
- Revenue Next Year
- OABI $48.89
- RDIB $10.86
- P/E Ratio
- OABI N/A
- RDIB N/A
- Revenue Growth
- OABI 3.36
- RDIB 7.59
- 52 Week Low
- OABI $1.22
- RDIB $5.78
- 52 Week High
- OABI $4.61
- RDIB $14.95
- Technical
- Relative Strength Index (RSI)
- OABI 49.87
- RDIB 50.69
- Support Level
- OABI $1.33
- RDIB $10.97
- Resistance Level
- OABI $1.64
- RDIB $12.21
- Average True Range (ATR)
- OABI 0.09
- RDIB 0.39
- MACD
- OABI 0.01
- RDIB -0.00
- Stochastic Oscillator
- OABI 55.92
- RDIB 64.32
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.